Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.
High risk, high reward S Korea to debut AI-boom linked ETFs
South Korea is launching its first single-stock leveraged ETFs, linked to chipmakers Samsung Electronics and SK Hynix, aiming to double daily stock movements. These products
May 25, 2026